Project description
Better diagnosis and treatment of blood clots could be around the corner
Blood clotting (coagulation) is an important process that protects us against excess external or internal bleeding when a blood vessel is damaged. However, when blood clots are traversing the circulatory system, hypoxia of downstream cells and tissues can occur with deadly results. Venous thromboembolism (VTE), including deep vein thrombosis and its life-threatening complication, pulmonary embolism, is among the most frequent causes of death in developed countries. We still do not know what triggers it, but hypoxia is known to play a role in clot formation. The EU-funded PROVE project is studying proteins and protein markers in human cells and blood samples from healthy individuals and patients with VTE to determine the effects of hypoxia on coagulation and the initiation of VTE. Outcomes are expected to lead to better diagnosis and treatment of this killer disease.
Objective
Venous thromboembolism (VTE) is a common, deadly condition affecting more than 1 million europeans, with 500.000 related deaths in EU per year. Many risk factors are established, but it is not known what triggers a VTE event, which hampers development of predictive and therapeutic measures. Hypoxia is known to play a major role in thrombus formation, but via which mechanisms is unclear. PROVE will be conducted at the university of Tromsø, using state-of-the-art equipment in a world-class thrombosis center of excellence (TREC) to uncover how hypoxia contributes to thrombus formation, with an emphasis on immunology and extracellular vesicles (EVs). TREC is composed of three units, combining epidemiology, clinic, and laboratory research, to conduct interdisciplinary, cutting-edge, research. PROVE will add aspects on immunology and EVs to TREC, two fields with greatly increasing importance in thrombotic research.
PROVE will address three research objectives: (i) To unravel processes and pathways triggered by IH in intravascular cells (i.e. endothelial cells, monocytes and platelets); (ii) To define the characteristics and procoagulant activity of cell-specific EVs derived from intravascular cells activated by VTE-associated stimuli including IH, (iii) To comprehensively compare cell-specific EVs isolated from plasma of VTE patients and healthy subjects, towards future development of diagnostic tools and improved treatment regimens.
This will be achieved by substantial characterizations and functional test of human cells and blood samples from both healthy individuals, and VTE patients. This will result in powerful data sets from protein expression analysis, and RNA sequencing, but also functional experiments to define effects of hypoxia on coagulation, and initiation of thrombi.
The long term goal of PROVE is to improve diagnostic and therapeutic procedures, to reduce the substantial suffering and costs of VTE.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine angiology vascular diseases
- medical and health sciences health sciences public health epidemiology
- natural sciences biological sciences cell biology
- medical and health sciences basic medicine immunology
- natural sciences biological sciences genetics RNA transcriptomes
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2019
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
9019 Tromso
Norway
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.